Insights into the Complications of SGLT-2 Inhibitors in Patients with Type 2 Diabetes: Real-World Outcomes
Abstract
Abstract Introduction: Diabetes mellitus (DM) has become a global health crisis, and according to the International Diabetes Federation (IDF), over 700 million adults are projected to have diabetes by 2045. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have emerged as a promising treatment; however, concerns have arisen regarding their safety and potential complications. This study aims to investigate the incidence of complications in patients with diabetes who are using SGLT-2 inhibitors. Methodology: A retrospective study was conducted at a university hospital, analyzing patients with diabetes who were on Empagliflozin and Dapagliflozin. The variables analyzed were divided into four sections.
Results:: In total, 167 patients with type 2 DM were included, all of whom were on SGLT-2 inhibitors for more than three months. The mean age of participants was 59 ± 10 years, and 29% were smokers of 32.0 ± 21.2 pack-years. The most common comorbidity was hypertension (54.3%). Approximately 27% of the patients developed urinary tract infections (UTIs), with female (64.9%) predominance compared to males (35.1%) (p = 0.004). Patients with UTIs were younger (mean age 54 ± 11.8 years) and had a shorter diabetes duration (12 ± 10 years) than those without UTIs (p ≤ 0.008). Only 5.8% of patients had foot infections, and 2.2% had foot ulcers. Laboratory results showed stable BUN, creatinine, and electrolyte levels, with significant improvements in lipid profiles at 6 and 12 months.…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.